[0025] The present invention also features Compound 1 or a pharmaceutically acceptable salt thereof for use to treat an HCV patient regardless of the specific HCV genotype(s) that the patient has. Such uses are illustrated in the first aspect of the invention described above, including each and every embodiment and example described thereunder.

[0026] The present invention further features Compound 1 or a pharmaceutically acceptable salt thereof for use to treat an HCV patient infected with HCV genotype 2, 3, 4, 5, or 6. Such uses are illustrated in the second aspect of the invention described above, including each and every embodiment and example described thereunder.


[0026a] In another aspect, there is provided a use of an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment for HCV, wherein the medicament is to be administered to an HCV patient, wherein said patient is not genotyped for said treatment.

[0026b] In another aspect, there is provided a use of an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of HCV, wherein the medicament is to be administered to an HCV patient, wherein said patient is infected with HCV genotype 2, 3, 4, 5, or 6.

[0027] Other features, objects, and advantages of the present invention are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating preferred embodiments of the invention, are given by way of illustration only, not limitation. Various changes and modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description.

DETAILED DESCRIPTION

[0028] Compound 1, also known as methyl {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-threonyl]pyrrolidin-2-yl}-1H-benzimidazol-5-yl)pyrrolidin-2-yl]-6-fluoro-1H-benzimidazol-2-yl}pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl}carbamate, is described in U.S. Patent Application Publication No. 2012/0004196, the entire content of which is incorporated herein by reference.



Compound 1

Compound 1 was found to have EC_{50} values of less than 10 pM against stable subgenomic replicons with NS5A from a broad range of clinically relevant HCV genotypes, such as

What is claimed is:

1. ~~A method of treatment for HCV, comprising administering~~ Use of an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment for HCV, wherein the medicament is to be administered to an HCV patient, wherein said patient is not genotyped for said treatment.

2. The ~~method~~ use of claim 1, wherein said patient is infected with HCV genotype 2.

3. The ~~method~~ use of claim 1, wherein said patient is infected with HCV genotype 3.

4. The ~~method~~ use of claim 1, wherein said patient is infected with HCV genotype 4.

5. The ~~method~~ use of claim 1, wherein said patient is infected with HCV genotype 5.

6. The ~~method~~ use of claim 1, wherein said patient is infected with HCV genotype 6.

7. The ~~method~~ use according to one of claims 1-6, where said Compound 1 or the salt thereof is to be co-administered with another anti-HCV agent.

8. The ~~method~~ use according to one of claims 1-6, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor or an HCV polymerase inhibitor.

9. The ~~method~~ use according to one of claims 1-6, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor and an HCV polymerase inhibitor.

10. The ~~method~~ use according to one of claims 1-6, wherein said treatment lasts for less than 24 weeks and does not include administration of interferon to said patient.

11. The ~~method~~ use according to one of claims 1-6, wherein said treatment lasts for no more than 12 weeks and does not include administration of interferon to said patient.

12. The ~~method~~ use according to one of claims 1-6, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor or a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, and wherein said treatment lasts for less than 24 weeks and does not include administration of interferon to said patient.

13. The ~~method~~ use according to one of claims 1-6, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor or a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, and wherein said treatment lasts for no more than 12 weeks and does not include administration of interferon to said patient.

14. ~~A method of treatment for HCV, comprising administering~~Use of an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of HCV, wherein the medicament is to be administered to an HCV patient, wherein said patient is infected with HCV genotype 2, 3, 4, 5, or 6.

15. The ~~method~~ use of claim 13, wherein said patient is infected with HCV genotype 2.

16. The ~~method~~ use of claim 13, wherein said patient is infected with HCV genotype 3.

17. The ~~method~~ use of claim 13, wherein said patient is infected with HCV genotype 4.

18. The ~~method~~ use of claim 13, wherein said patient is infected with HCV genotype 5.

19. The ~~method~~ use of claim 13, wherein said patient is infected with HCV genotype 6.

20. The ~~method~~ use according to one of claims 14-19, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor or a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, and wherein said treatment lasts for less than 24 weeks and does not include administration of interferon to said patient.

21. The ~~method~~ use according to one of claims 14-19, wherein said Compound 1 is to be co-administered with an HCV protease inhibitor or a combination of an HCV protease inhibitor and an HCV polymerase inhibitor, and wherein said treatment lasts for no more than 12 weeks and does not include administration of interferon to said patient.